DMX-250

N/A

Report date: 2022/08/24 20:00:31

Base Information

Drug NameDMX-250
Drug Alias NameN/A
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionAngiotensin II receptor antagonistsC-C chemokine receptor type 2 antagonists
TargetsAngiotensin II receptorC-C chemokine receptor type 2
Therapy Area/IndicationsMetabolic Dysfunction-Associated Steatotic Liver Disease
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryAustralia
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesDimerix Bioscience Pty Ltd
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesDimerix Bioscience Pty Ltd
Active IndicationsN/A
Inactive IndicationsMetabolic Dysfunction-Associated Steatotic Liver Disease

Other Information

ATC CodeN/A
Related LinksN/A